BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

...diseases 2012 Improved Pregnancy Outcomes via Early Detection (IMPROvED) consortium accelopment AG; Metabolomic Diagnostics Ltd.; Pronota N.V....
BioCentury | Sep 8, 2014
Company News

Biocartis, Pronota diagnostic news

...Biocartis spun out newco MyCartis (Lausanne, Switzerland), a combination of Pronota and Biocartis' Evalution unit, which...
...and nucleic acid-based biomarker analysis. The technology was previously known as Dynamic Multi-Analyte Technology (DMAT). Pronota...
...patients. Idylla (formerly Apollo) is an automated molecular diagnostic system. Biocartis S.A. , Lausanne, Switzerland Pronota N.V....
BioCentury | Sep 5, 2014
Company News

Biocartis raises EUR 64.5M, spins out newco

...investors also participated (see BioCentury, Nov. 18, 2013) . Newco MyCartis is a combination of Pronota N.V....
...and nucleic acid-based biomarker analysis. The technology was previously known as Dynamic Multi-Analyte Technology (DMAT). Pronota...
BioCentury | Nov 12, 2012
Company News

Metabolomic Diagnostics Ltd., Pronota diagnostic news

...Detection (IMPROvED) consortium to develop a predictive preeclampsia diagnostic. The project, which includes Metabolomic and Pronota...
...time. The partners could not be reached for details. Metabolomic Diagnostics Ltd. , Cork, Ireland Pronota N.V....
BioCentury | Jul 23, 2012
Clinical News

Mid-gestation pre-eclampsia screening test diagnostic data

...A validation study in 300 women showed that Pronota's mid-gestation preeclampsia screening test correctly identified 80%...
...information from 5,600 women in Australia, New Zealand, the U.K. and Ireland over 8 years. Pronota N.V....
BioCentury | Mar 26, 2012
Company News

Pronota management update

Pronota N.V. , Zwijnaarde, Belgium Business: Diagnostic, Pharmacogenetics Hired: Carol Greve-Philips as CBO, formerly VP of corporate development at Genzyme Corp. , which Sanofi acquired; and Els Hubloux as CFO, formerly senior investment manager at Capricorn Venture...
BioCentury | Feb 28, 2011
Company News

Pronota, Mitsubishi Chemical deal

...Chemical Holdings' Molecuence Corp. subsidiary partnered to discover and validate protein biomarkers to diagnose stroke. Pronota...
...protein biomarker discovery platform and MASSterclass protein biomarker verification tool. Further terms were not disclosed. Pronota N.V....
BioCentury | May 24, 2010
Financial News

Pronota financial update

...the total raised in the round to €7.9 million. MedSciences Capital participated in the close. Pronota N.V....
BioCentury | Nov 9, 2009
Financial News

Pronota financial update

...Venture Management participated. The company raised €4.9 million ($6.9 million) in the round in June. Pronota N.V....
BioCentury | Jul 6, 2009
Financial News

Pronota completes venture financing

Pronota N.V. , Zwijnaarde, Belgium Business: Diagnostic, Pharmacogenetics Date completed: 6/29/09 Type: Venture financing Raised: €4.9 million ($6.9 million) Investors: LSP-Life Sciences Partners; Gimv N.V.; Biotech Fund Flanders; KBC Private Equity; Johnson & Johnson Development Corp.;...
Items per page:
1 - 10 of 26
BioCentury | Jan 15, 2015
Finance

Consortia cross-talk

...diseases 2012 Improved Pregnancy Outcomes via Early Detection (IMPROvED) consortium accelopment AG; Metabolomic Diagnostics Ltd.; Pronota N.V....
BioCentury | Sep 8, 2014
Company News

Biocartis, Pronota diagnostic news

...Biocartis spun out newco MyCartis (Lausanne, Switzerland), a combination of Pronota and Biocartis' Evalution unit, which...
...and nucleic acid-based biomarker analysis. The technology was previously known as Dynamic Multi-Analyte Technology (DMAT). Pronota...
...patients. Idylla (formerly Apollo) is an automated molecular diagnostic system. Biocartis S.A. , Lausanne, Switzerland Pronota N.V....
BioCentury | Sep 5, 2014
Company News

Biocartis raises EUR 64.5M, spins out newco

...investors also participated (see BioCentury, Nov. 18, 2013) . Newco MyCartis is a combination of Pronota N.V....
...and nucleic acid-based biomarker analysis. The technology was previously known as Dynamic Multi-Analyte Technology (DMAT). Pronota...
BioCentury | Nov 12, 2012
Company News

Metabolomic Diagnostics Ltd., Pronota diagnostic news

...Detection (IMPROvED) consortium to develop a predictive preeclampsia diagnostic. The project, which includes Metabolomic and Pronota...
...time. The partners could not be reached for details. Metabolomic Diagnostics Ltd. , Cork, Ireland Pronota N.V....
BioCentury | Jul 23, 2012
Clinical News

Mid-gestation pre-eclampsia screening test diagnostic data

...A validation study in 300 women showed that Pronota's mid-gestation preeclampsia screening test correctly identified 80%...
...information from 5,600 women in Australia, New Zealand, the U.K. and Ireland over 8 years. Pronota N.V....
BioCentury | Mar 26, 2012
Company News

Pronota management update

Pronota N.V. , Zwijnaarde, Belgium Business: Diagnostic, Pharmacogenetics Hired: Carol Greve-Philips as CBO, formerly VP of corporate development at Genzyme Corp. , which Sanofi acquired; and Els Hubloux as CFO, formerly senior investment manager at Capricorn Venture...
BioCentury | Feb 28, 2011
Company News

Pronota, Mitsubishi Chemical deal

...Chemical Holdings' Molecuence Corp. subsidiary partnered to discover and validate protein biomarkers to diagnose stroke. Pronota...
...protein biomarker discovery platform and MASSterclass protein biomarker verification tool. Further terms were not disclosed. Pronota N.V....
BioCentury | May 24, 2010
Financial News

Pronota financial update

...the total raised in the round to €7.9 million. MedSciences Capital participated in the close. Pronota N.V....
BioCentury | Nov 9, 2009
Financial News

Pronota financial update

...Venture Management participated. The company raised €4.9 million ($6.9 million) in the round in June. Pronota N.V....
BioCentury | Jul 6, 2009
Financial News

Pronota completes venture financing

Pronota N.V. , Zwijnaarde, Belgium Business: Diagnostic, Pharmacogenetics Date completed: 6/29/09 Type: Venture financing Raised: €4.9 million ($6.9 million) Investors: LSP-Life Sciences Partners; Gimv N.V.; Biotech Fund Flanders; KBC Private Equity; Johnson & Johnson Development Corp.;...
Items per page:
1 - 10 of 26